MEN2B Added to Generation Study

After discussions in late 2024 with the team behind the Genomics England’s Generation Study, we are delighted to share that MEN2B (RET mutation number 918) will be added to the testing panel from March 2026. Given that the average age of diagnosis for MEN2B is currently age 13, by which time disease has spread, this is a chance to detect the disease in new born babies in time to treat them through thyroid surgery to improve long-term outcomes. We welcome this addition to the study, and, as ever, stand ready to support and families who receive a diagnosis of MEN2B.
- All our information on MEN2B can be found on this website and is available for children and adults.
- Support services are available to registered members of AMEND
.

Find out more about Genomics England